Screener
Corcept Therapeutics CORT Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Cash paid for operating lease liabilities | $413 | $371 | $795 | $618 |
| Recognition of right-of-use asset in exchange for lease liability | — | — | $2,868 | — |
| Weighted-average remaining lease term | 48 months | 60 months | ||
| Weighted-average discount rate | 8.3% | 8.5% |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's operating lease ROU assets?
- Corcept Therapeutics (CORT) reported operating lease ROU assets of 8.3% in Q2 2026.
- How has Corcept Therapeutics's operating lease ROU assets changed year-over-year?
- Corcept Therapeutics's operating lease ROU assets decreased by 2.4% year-over-year, from 8.5% to 8.3%.
- What is the long-term trend for Corcept Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), Corcept Therapeutics's operating lease ROU assets has grown at a 12.8% compound annual growth rate (CAGR), from 250,900,000% to 458,300,000%.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Corcept Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude